Immunotherapy with NK cells: recent developments in gene modification open up new avenues

被引：29
作者：
Reindl, Lisa Marie [1 ,2 ]
Albinger, Nawid [1 ,2 ]
Bexte, Tobias [1 ,2 ]
Mueller, Stephan [1 ,2 ]
Hartmann, Jessica [3 ]
Ullrich, Evelyn [1 ,2 ,4 ]
机构：
[1] Goethe Univ Frankfurt, Childrens Hosp, Frankfurt, Germany
[2] Goethe Univ Frankfurt, Expt Immunol, Frankfurt, Germany
[3] Paul Ehrlich Inst, Div Med Biotechnol, Langen, Germany
[4] Goethe Univ, Frankfurt Canc Inst, Frankfurt, Germany
来源：
ONCOIMMUNOLOGY | 2020年 / 9卷 / 01期
关键词：
CAR; NK cells; NK-92; cells; cell therapy; NATURAL-KILLER-CELL; CHIMERIC ANTIGEN RECEPTOR; T-CELLS; MESSENGER-RNA; NK-92; CELLS; HEMATOPOIETIC-CELLS; CORD BLOOD; IN-VITRO; ADOPTIVE TRANSFER; VIVO EXPANSION;
D O I：
10.1080/2162402X.2020.1777651
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chimeric antigen receptor (CAR)-T cell therapies have achieved remarkable success. However, application-related toxicities, such as cytokine release syndrome or neurotoxicity, moved natural killer (NK) cells into focus as novel players in immunotherapy. CAR-NK cells provide an advantageous dual killing-capacity by CAR-dependent and -independent mechanisms and induce few side effects. While the majority of trials still use CAR-T cells, CAR-NK cell trials are on the rise with 19 ongoing studies worldwide. This review illuminates the current state of research and clinical application of CAR-NK cells, as well as future developmental potential.
引用
收藏
页数：12
相关论文
共 120 条
  • [1] The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules:: implications for tumor immune escape
    Algarra, I
    García-Lora, A
    Cabrera, T
    Ruiz-Cabello, F
    Garrido, F
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (10) : 904 - 910
  • [2] Antony GK, 2010, CURR MED CHEM, V17, P3297
  • [3] Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO
  • [4] 2-A
  • [5] Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
    Balakrishnan, Ashwini
    Rajan, Anusha
    Salter, Alexander I.
    Kosasih, Paula L.
    Wu, Qian
    Voutsinas, Jenna
    Jensen, Michael C.
    Pluckthun, Andreas
    Riddell, Stanley R.
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7506 - 7516
  • [6] A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy
    Bari, Rafijul
    Granzin, Markus
    Tsang, Kam Sze
    Roy, Andre
    Krueger, Winfried
    Orentas, Rimas
    Pfeifer, Rita
    Moeker, Nina
    Verhoeyen, Els
    Dropulic, Boro
    Leung, Wing
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [7] BEANO A, 2008, J TRANSL MED, V6, DOI DOI 10.1186/1479-5876-6- 25
  • [8] Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns
    Bengsch, Bertram
    Ohtani, Takuya
    Herati, Ramin Sedaghat
    Bovenschen, Niels
    Chang, Kyong-Mi
    Wherry, E. John
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2018, 453 : 3 - 10
  • [9] The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
    Benson, Don M., Jr.
    Bakan, Courtney E.
    Mishra, Anjali
    Hofmeister, Craig C.
    Efebera, Yvonne
    Becknell, Brian
    Baiocchi, Robert A.
    Zhang, Jianying
    Yu, Jianhua
    Smith, Megan K.
    Greenfield, Carli N.
    Porcu, Pierluigi
    Devine, Steven M.
    Rotem-Yehudar, Rinat
    Lozanski, Gerard
    Byrd, John C.
    Caligiuri, Michael A.
    [J]. BLOOD, 2010, 116 (13) : 2286 - 2294
  • [10] REJECTION OF CLASS-I MHC-DEFICIENT HEMATOPOIETIC-CELLS BY IRRADIATED MHC-MATCHED MICE
    BIX, M
    LIAO, NS
    ZIJLSTRA, M
    LORING, J
    JAENISCH, R
    RAULET, D
    [J]. NATURE, 1991, 349 (6307) : 329 - 331
12345678910